Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7674650 | 0.82 | TSHR (0.39) | GAATSHRHTTSMN1; SMN2MAPT | |
| SCHEMBL28094372 | 0.81 | POLB (0.44) | GAATSHRHTTSMN1; SMN2MAPT | |
| SCHEMBL12466487 | 0.81 | SMN1; SMN2 (0.38) | GAATSHRHTTSMN1; SMN2MAPT | |
| SCHEMBL287221 | 0.79 | SMN1; SMN2 (0.37) | GAATSHRHTTSMN1; SMN2MAPT | |
| SCHEMBL5252228 | 0.79 | CYP19A1 (0.55) | TSHRHTTSMN1; SMN2ALDH1A1CYP19A1 | |
| SCHEMBL3717744 | 0.78 | SMN1; SMN2 (0.36) | GAATSHRHTTSMN1; SMN2MAPT | |
| SCHEMBL561018 | 0.77 | CYP19A1 (0.48) | TSHRHTTTTRSMN1; SMN2MAPT | |
| SCHEMBL716259 | 0.77 | CYP19A1 (0.54) | TSHRHTTTTRSMN1; SMN2MAPT | |
| SCHEMBL24534037 | 0.77 | ALDH1A1 (0.39) | GAATSHRHTTSMN1; SMN2MAPT | |
| SCHEMBL14782135 | 0.75 | POLB (0.49) | TSHRSMN1; SMN2MAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342116-B2 | Process for producing heterocyclic aldehyde | KOEI CHEMICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | KOEI CHEMICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | ADH1C, ADH1A, AOX1 | GAA 4683/4885TSHR 2066/4885HTT 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.